T.O.-based drug-maker names replacement CFO
Amgen still stirring over Nanula's coming departure

Amgen announced Tuesday the appointment of Robert Bradway as executive vice president and chief financial officer for the Thousand Oaks-based company.

Bradway replaces Richard Nanula and will be responsible for Amgen's finance, strategy and investor relations operations.

Nanula departs in the wake of a five-month corporate decline in which the world's largest biotechnology firm has seen its stock price plummet from a 52week high of $77 per share last October to $57.12 at the close of Tuesday's trading.

Amgen's two biggest drugs, Aranesp and Epogen, have come under heavy fire recently due to safety concerns. Aranesp treats anemia in cancer and Epogen helps patients with kidney failure.

The drugs account for almost half of the more than $15 billion in annual sales at Amgen.

Bradway, 44, joined Amgen in 2006 as vice president for corporate operations strategy. Prior to joining the company he spent 18 years at Morgan Stanley in New York and London, where he was a managing director in investment banking.

Bradway led Morgan Stanley's healthcare practice in Europe for several years and also ran the company's European banking department.

"Bob brings nearly 20 years of corporate finance experience to his new role and we are delighted to have him as part of our executive team," said Kevin Sharer, Amgen's chairman and chief executive officer.

Nanula will remain at Amgen for the next 90 days to assist in the transition.

"Richard has played an important role in Amgen's growth during the past six years, and I deeply appreciate his service to the company," Sharer said.